Mail

UK markets open in 5 hours 52 minutes

NIKKEI 225
38,242.79
+690.63(+1.84%)
HANG SENG
16,828.93
+317.24(+1.92%)
CRUDE OIL
83.44
+0.08(+0.10%)
GOLD FUTURES
2,334.30
-7.80(-0.33%)
DOW
38,503.69
+263.71(+0.69%)
Bitcoin GBP
53,632.88
-275.55(-0.51%)

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Accuray Incorporated (ARAY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

2.2200

+0.0500

(+2.30%)

At close: 04:00PM EDT

2.2200

0.00

(0.00%)

After hours:

04:20PM EDT

Full screen

Trade prices are not sourced from all markets

Previous close	2.1700
Open	2.1800
Bid	2.2000 x 400
Ask	2.2300 x 200
Day's range	2.1700 - 2.2500
52-week range	2.1000 - 4.3000
Volume	413,163
Avg. volume	485,322

Market cap	220.155M
Beta (5Y monthly)	1.47
PE ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings date	N/A
Forward dividend & yield	N/A (N/A)
Ex-dividend date	N/A
1y target est	N/A

All

News

Press releases

PR Newswire
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzerland, that will serve as the European education hub for radiosurgery and radiotherapy product training, and sharing of best practices and innovative techniques using the latest model Accuray CyberKnife® and Radixact® Radiation Treatment Delivery Systems and Accuray Precision® Treatment Planning System. The Genolier based cen
PR Newswire
Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 1, 2024.
PR Newswire
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System
Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to

NIKKEI 22538,242.79+690.63(+1.84%)

HANG SENG16,828.93+317.24(+1.92%)

CRUDE OIL83.44+0.08(+0.10%)

GOLD FUTURES2,334.30-7.80(-0.33%)

DOW38,503.69+263.71(+0.69%)

Bitcoin GBP53,632.88-275.55(-0.51%)

What is the true cost of the UK state pension?

Accuray Incorporated (ARAY)

Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland

Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024

New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System

NIKKEI 225
38,242.79
+690.63(+1.84%)

HANG SENG
16,828.93
+317.24(+1.92%)

CRUDE OIL
83.44
+0.08(+0.10%)

GOLD FUTURES
2,334.30
-7.80(-0.33%)

DOW
38,503.69
+263.71(+0.69%)

Bitcoin GBP
53,632.88
-275.55(-0.51%)